BioMarin Pharmaceutical Inc. SG&A Expenses

SG&A Expenses of BMRN for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending March 31, 2022 was $195 Million (a -10.55% decrease compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 7.38%
  • Annual SG&A Expenses for 2021 was $759 Million (a 3.6% increase from previous year)
  • Annual SG&A Expenses for 2020 was $733 Million (a 9.08% increase from previous year)
  • Annual SG&A Expenses for 2019 was $672 Million (a 9.45% increase from previous year)
  • Twelve month SG&A Expenses ending March 31, 2022 was $777 Million (a 2.11% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 5.71% year-over-year
Trailing SG&A Expenses for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$777 Million $761 Million $739 Million $735 Million
Visit stockrow.com/BMRN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of BioMarin Pharmaceutical Inc.

Most recent SG&A Expensesof BMRN including historical data for past 10 years.

Interactive Chart of SG&A Expenses of BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $194.62
2021 $217.56 $183.33 $181.25 $178.59 $759.38
2020 $195.51 $179.45 $175.41 $187.3 $733.0
2019 $187.9 $170.11 $160.75 $162.16 $672.0
2018 $164.17 $148.57 $153.28 $138.34 $614.0
2017 $160.28 $130.53 $143.51 $120.02 $565.0
2016 $142.96 $118.76 $109.58 $105.3 $476.59
2015 $113.91 $94.04 $101.51 $92.81 $402.27
2014 $99.39 $74.6 $68.09 $60.07 $302.16
2013 $71.81 $61.84 $50.66 $51.05 $235.36
2012 $55.05 $46.34 $51.54 $45.25 $198.17
2011 $48.49 $44.88 $41.02 $175.42

Business Profile of BioMarin Pharmaceutical Inc.

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.